Advancing Therapies for Patients

Find a clinical trial

Molecular Profiling

page image
shadow image

Text Size

minus image

plus image

plus image


Print image

Email a Friend

Molecular Profiling Lab

Molecular profiling has emerged to play a pivotal role in personalised medicine, classifying tumours based on genetic profiles for the purposes of diagnosing and treating cancers, or predicting response to therapy. Innovative technologies, including next generation sequencing, can now be used clinically to identify an extensive panel of actionable and exploratory genetic alterations.

In the UK, Sarah Cannon is working with University College London - Advanced Diagnostics (UCL-AD), a CPA-accredited molecular profiling laboratory, to develop novel technologies and assay menus and provide a clinical service to the private sector and the NHS, as well as a comprehensive research platform to the pharmaceutical industry.

Read more about the launch of this lab >>

This lab was also featured on ITV News on May 6, 2013 >>

Sarah Cannon/UCL Molecular Profiling Research Laboratories currently conducts next generation sequencing (NGS) of 22 genes, with further gene panels to be added to support both the clinical and research environment.

The menu of assays that are currently available includes:


Next Generation Sequencing mutation analysis; 22- gene panel: 

  • AKT1
  • ALK
  • BRAF
  • CTNNB1
  • DDR2
  • EGFR 
  • ERBB2 
  • ERBB4 
  • FBXW7 
  • FGFR1 
  • FGFR2 
  • FGFR3 
  • KRAS 
  • MAP2K1 
  • MET
  • NOTCH1 
  • NRAS
  • PIK3CA
  • PTEN
  • SMAD4
  • STK11
  • TP53
  • HER2 expression analysis for HER2 targeted therapies
  • EGFR wildtype expression analysis
  • ALK translocation induced over-expression analysis for ALK targeted therapies
  • ER/PR expression analysis for endocrine therapy
  • MET expression analysis for MET targeted therapies
  • Ki67 staining for proliferation indices
  • PTEN expression analysis
  • HER2 gene amplification analysis for HER2 targeted therapies
  • EGFR wildtype gene amplification analysis
  • ALK gene rearrangement analysis for ALK targeted therapies
  • ROS1 gene rearrangement analysis for ROS1 targeted therapies
  • MET gene amplification analysis for MET targeted therapies
  • HAEMPATH probes for haematopathology profiling for MYC, BCL2, BCL6, MALT1, CCND1, IgH and ALK

To order the 22-gene panel, please complete the request form by following this link >>

For a list of frequently asked questions and answers about the Sarah Cannon UCL Advanced Diagnostics Molecular Profiling Laboratory and next generation sequencing, please follow this link >>

With access to thousands of patients with different tumor types and the technical capabilities of this laboratory, we are able to rapidly identify eligible patients for early and late-phase clinical trials and explore novel biomarkers that predict response to specific treatments.

Latest Videos

watch the latest videos.

Learn more


news from the industry.

Read more

hero1 image
Sarah Cannon Research UK NHS Ventures
University College London Hospitals